Brought to you by:
Veterans with claudication who undergo revascularization ‘significantly more likely to have major amputation than those who do not’
Patients within the Veterans Affairs Administration healthcare system who underwent an intervention for intermittent claudication (IC) were consistently at three-to-four times greater risk of undergoing subsequent amputation compared to those who did not, researchers at Stanford University report. Furthermore, Intervention…
PRISTINE registry with Selution SLR sirolimus drug-eluting balloon completes enrollment
MedAlliance has announced completion of patient enrollment in the PRISTINE clinical trial with the Selution SLR 018 drug-eluting balloon (DEB) for the treatment of patients with below-the-knee (BTK) disease. According to a MedAlliance press release, Selution SLR is the first DEB to be…
LimFlow system a ‘cost-effective and high-value alternative’ to traditional therapies
Percutaneous deep vein arterialization (pDVA) with the LimFlow system offers a cost-effective and high-value alternative to traditional therapies or amputation, according to a recent study published in the Journal of Critical Limb Ischemia. Peter Schneider, MD, professor of surgery at…
Latest meta-analysis on paclitaxel in peripheral arterial disease provokes mixed reception
“There appears to be heightened risk of major amputation after use of paclitaxel-coated balloons [PCBs] in the peripheral arteries,” findings from a systematic review and meta-analysis of randomized controlled trials (RCTs) published in the European Journal of Vascular and Endovascular…
Introducing patient-reported outcomes into the VQI
Vascular specialists have long recognized that there is more to the treatment of peripheral arterial disease (PAD) than the immediate procedural success and early outcomes. The patient experience should not only be measured in clinical outcomes such as patency or…
Philips announces positive two-year data from TOBA II BTK clinical trial
Royal Philips recently announced positive two-year results from the TOBA (Tack optimized balloon angioplasty) II below-the-knee (BTK) clinical trial. The data show the Philips Tack endovascular system (4F), a first-of-its kind dissection repair device, provides a sustained treatment effect and positive…
One-year results from PROMISE I study of LimFlow system in ‘no-option’ CLTI patients published
Twelve-month data from the full patient cohort in the PROMISE I study of the LimFlow percutaneous deep vein arterialization (pDVA) system have been published in the Journal of Vascular Surgery. Results showed sustained positive outcomes for both amputation-free survival and…
Intermittent claudication and exercise therapy: A poor SET-up
Many of you may have already heard about the controversial Comparative Billing Reports (CBRs) that have been received by some of our vascular surgery colleagues. In case you haven’t, this is your chance to catch up and to prepare for…
Innovation: ISET audience hears what’s on the horizon for CLTI patients
“I am going to give you reasons to be excited about your critical limb practice,” Peter Schneider, MD, professor of vascular and endovascular surgery at the University of California San Francisco, told delegates attending the International Symposium on Endovascular Therapy…
MicroStent to treat PAD below the knee receives FDA breakthrough device designation
Micro Medical Solutions (MMS) recently revealed Food and Drug Administration (FDA) breakthrough device designation for its MicroStent vascular stent. This novel technology is designed to achieve and maintain vessel patency, enhance wound treatment and improve quality of life and blood…